NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. is engaged in developing and marketing innovative anti-infective products for ophthalmic conditions, focusing on improving eye health through specialized solutions. Founded in 2000 and headquartered in Emeryville, US, NovaBay Pharmaceuticals, Inc. develops anti-infective products primarily for eye health.

There are no current mentions of pivots or subsidiaries. The company was established by individuals whose specific identities are not disclosed. It has achieved significant funding milestones, and the total funding raised is reflected in recent financing rounds without specifying their names. NovaBay Pharmaceuticals, Inc.

specializes in developing and commercializing innovative anti-infective products, primarily targeting ophthalmic conditions. Their core product is Avenova, an eyelid and lash hygiene solution that cleanses and supports eye health by targeting bacteria associated with eyelid infections and conditions like blepharitis. Avenova is marketed to both healthcare professionals and directly to consumers, particularly aimed at those with persistent eye problems, including dry eye syndrome. The product is primarily sold in the United States, with potential distribution in international markets.

In the most recent fiscal year of 2023, NovaBay Pharmaceuticals reported revenue of USD 14. 73 mn, alongside an EBITDA of USD -7. 39 mn. Their revenue generation strategy includes direct-to-consumer sales and partnerships with healthcare providers and retail pharmacies, bolstered by recommendations from ophthalmologists and optometrists, ensuring access to their specialized anti-infective solutions.